Abstract
Erlotinib is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. Efficacy of this drug was documented in the BR.21 trial showing that adenocarcinoma, female gender, Asian ethnicity and never-smoker status are predictive of clinical response to erlotinib. Retrospective studies documented the same benefits for elderly patients as young patients in terms of response, progression-free survival, and overall survival. The primary aim of our trial was to confirm these findings in a prospective way; the secondary aim was to identify if the aforementioned clinical characteristics may be predictive of response even in elderly patients. The trial included 31 patients with pretreated stage IIIB (2) and IV (29) non-small cell lung cancer (NSCLC). Median age was 75 years (range: 65–85). Twenty-seven patients were current/former-smokers and four never-smokers. Twenty-three patients are evaluable for response. Objective response rates were reported in five patients (16%). Five patients had stable disease (16%) and 13 progressive disease (43%). Seven patients had a “clinical benefit” from erlotinib (22.5%; 95% C.I.: 7.9–37.2%). Grade 3 skin rash was recorded in three patients (10%). Median survival was 9 months (range 1–30). Median time to progression was 3 months (range: 1–24 months). Our study confirmed erlotinib activity and safety as second- and third-line treatment in elderly patients with advanced NSCLC, especially in terms of median survival. Even though this trial does not allow us to draw a definitive conclusion about the role of a particular clinical characteristic predictive of response, the “clinical benefit” was documented especially in females, in patients with adenocarcinoma histology and skin rash, confirming previous retrospective data.
Similar content being viewed by others
References
Jemal A, Siegel R, Ward E et al (2007) Cancer statistics. CA Cancer J Clin 57:43–66
Hutchins LF, Unger JM, Crowley JJ et al (1999) Under-representation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med 341:2061–2067
Lewis JH, Kilgore ML, Goldman DP et al (2003) Participation of patients 65 years of age or older in cancer clinical trials. J Clin Oncol 21:1383–1389
The Elderly Lung Cancer Vinorelbine Italian Study Group (1999) Effects of Minorenne on quality of life and survival of elderly patients with advanced non-small-cell lung cancer. J Natl Cancer Inst 91:66–72
Gridelli C, Perrone F, Gallo C et al (2003) Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial. J Natl Cancer Inst 95:362–372
Shepherd FA, Dancey J, Ramlau R et al (2000) Prospective randomized trial of doxetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 18:2095–2103
Fossella FV, DeVore R, Kerr R et al (2000) Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing regimens. The TAX 320 Non-Small-Cell Lung Cancer Study Group. J Clin Oncol 18:2354–2362
Hanna N, Shepherd FA, Fossella FV et al (2004) Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small cell lung cancer previously treated with chemotherapy. J Clin Oncol 22:1589–1597
Shepherd FA, Rodrigues-Pereira J, Ciuleanu T et al (2005) Erlotinib in previously treated non-small cell lung cancer. N Engl J Med 353:123–132
Kim ES, Hirsh V, Mok T et al (2008) Gefitinib versus docetaxel in previously treated non-small cell-lung cancer (INTEREST): a randomised phase III trial. Lancet 372(9652):1809–1818
Wheatley-Price P, Ding K, Seymour L et al (2008) Erlotinib for advanced non-small cell lung cancer in the elderly: an analysis of the National Cancer Institute of Canada Clinical Trials Group Study Br. 21. J Clin Oncol 26:2350–2357
Perng RP, Yang CH, Chang GC et al (2008) High efficacy of erlotinib in Taiwanese NSCLC patients in an expanded access program study previously treated with chemotherapy. Lung Cancer 62:78–84
Miller AB, Hoogstraten B, Staquet M et al (1981) Reporting results of cancer treatment. Cancer 47:207–214
Gridelli C, Maione P, Illiano A et al (2007) Cisplatin plus gemcitabine or vinorelbine for elderly patients with advanced non-small-cell lung cancer: the MILES-2P studies. J Clin Oncol 25:4663–4669
Lilenbaum RC, Herndon JE 2nd, List MA et al (2005) Single-agent versus combination chemotherapy in advanced non-small-cell lung cancer: The Cancer and Leukemia Group B (study 9730). J Clin Oncol 23:190–196
Gridelli C, Shepherd FA (2005) Chemotherapy for elderly patients with non-small cell lung cancer: a review of the evidence. Chest 128:947–957
Asmis T, Ding K, Shepherd F et al (2005) Are age and co-morbidity prognostic factors in the treatment of metastatic non-small-cell lung cancer (NSCLC): a review of a National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG) randomized trial. Lung Cancer 49:S85
Weiss GJ, Langer C, Rosell R et al (2006) Elderly patients benefit from from second-line cytotoxic chemotherapy: a subset analysis of a randomized phase III trial of pemetrexed compared with docetaxel in patients with previously treated advanced non-small cell lung cancer. J Clin Oncol 24:4405–4411
Scagliotti GV, Parikh P, von Pawel J et al (2008) Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced non-small-cell lung cancer. J Clin Oncol 26:3543–3551
Olayioye MA, Neve RM, Lane HA et al (2000) The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J 19:3159–3167
Conflict of interest statement
No funds were received in support of this study and no benefits in any form have been or will be received from a commercial party related to the subject of this paper.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Rossi, D., Dennetta, D., Ugolini, M. et al. Activity and safety of erlotinib as second- and third-line treatment in elderly patients with advanced non-small cell lung cancer: a phase II trial. Targ Oncol 5, 231–235 (2010). https://doi.org/10.1007/s11523-010-0163-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11523-010-0163-4